Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
This Stock Just Dropped By 15%: Is It a Buy?
Now could be a great opportunity to buy low. 
Via The Motley Fool
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? 
Via Chartmill
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Sanofi Crashes 16% As Third Quarter Comes In Light Ahead Of Spinoff
The company announced plans to spin off its consumer health division. 
Via Investor's Business Daily
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today?
MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million  
Via Benzinga
Sanofi (SNY) Q3 2023 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
Microsoft, Google, Amazon and Meta led big earnings. 
Via Investor's Business Daily
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. 
Via Benzinga
Why Are Stocks Up Today?
Stocks are up on Friday as investors react to a positive earnings report from Amazon that has other tech stocks moving in sympathy with AMZN. 
Via InvestorPlace
Why Is Nikola (NKLA) Stock Up 4% Today?
Nikola stock is on the rise Friday as shares of NKLA continue a climb this week on positive news of $165 million award from a court case. 
Via InvestorPlace
Preview: Sanofi's Earnings
Via Benzinga
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual... 
Via Benzinga
Sanofi Goes The Rival Way: Plans Separation Of Consumer Healthcare Unit
Sanofi SA (NASDAQ: SNY) plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday! 
Via InvestorPlace
Nasdaq, S&P 500 Eye Rebound While Bitcoin Edges Down: Amazon's Q3 Lifts Tech Stocks As Traders Eye Fed's Favorite Inflation Gauge
As Amazon, Inc. (NASDAQ:AMZN) hawked good tidings, the negative sentiment in the equity market appears to have reversed. The recovery could be in part due to traders looking for bargains following a... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Ford, Sanofi, Enphase Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Earnings Scheduled For October 27, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion. 
Via Benzinga
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating. 
Via Investor's Business Daily
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.